Chemistry: analytical and immunological testing – Including chromatography
Reexamination Certificate
2000-09-07
2004-09-14
Ludlow, Jan M. (Department: 1743)
Chemistry: analytical and immunological testing
Including chromatography
C436S092000, C436S093000, C436S096000, C436S098000, C436S164000, C436S175000, C436S177000
Reexamination Certificate
active
06790668
ABSTRACT:
The present invention relates to methods of determining the concentration of a selected drug in the body of a subject to provide the monitoring of either drug levels in a clinical setting and in public health services and patient compliance with medication prescriptions. The methods are characterized by a simplified and effective deproteinizing body fluid step followed by drug extraction and measurement using an accurate technique, such as a colorimetric assay or a High-Performance Liquid Chromatography method.
BACKGROUND OF THE INVENTION
In the field of medicine, a number of medications have been found safe and efficacious for the treatment of patients with physical illnesses. Patients placed on prescribed medication treatment plans are typically monitored. Subjective and objective methods are used to identity bothersome symptoms and to implement any changes necessary during the course of treatment. Monitoring may continue for as long as treatment is provided.
Currently, the most common method of monitoring patients for medication compliance is clinical observation which involves individual counseling and close personal supervision by physicians which observe physiological signs and symptoms or residual signs of illness and also listen to patient complaints regarding degree of pain relief and evaluate physiological changes over time. This method is time consuming, expensive and highly subjective. Needless to say, it is fraught with potential errors.
Additional compliance information can also be obtained using qualitative urine monitoring methods such as the standard laboratory procedure called enzyme-multiplied immunoassay (EMIT). Utilizing an arbitrary cutoff value, these methods provide the clinician with a simple positive or negative indication of the possible presence or absence of a parent drug or its metabolites in a patient's urine. The parent drug is the prescribed medication itself and the metabolites are those chemical derivatives of the medication which naturally occur upon the patient's body metabolizing the medication. These tests do not provide information concerning the time or amount of last drug use or whether or not the prescribed dose of medication was ingested properly, diverted or supplemented.
Physicians utilizing only clinical evaluation and qualitative urine drug screening test results may develop problems in their treatment methods. Consistently, Fox, W. (Fox, W. (1990). “Drug combinations and bioavailability of rifampicin”. Tubercle. 71: 241-5) suggested parallel serum/plasma sampling in selected studies for testing abroad to verify the tuberculosis treatment effectiveness using drug combinations by confirming the urinary bioavailability determination. In the mentioned text, the term “abroad” means outside developing countries in which expensive analytical equipment is not commonly found.
Another monitoring method sometimes used is a direct measurement of parent drug concentrations or active metabolites concentrations of the drug in plasma and other body fluids. This direct method presents some limitations since it is expensive and requires the use of time consuming and highly technical analytical procedures such as high-performance liquid chromatography and mass spectrometry since active and inactive metabolites must be quantified separately.
Attempts have been made to overcome the difficulties of the sophisticated analytical procedures. In the EP 122 032, it is described a method of determining the concentration of a selected drug in the body of a subject consisting of the steps of holding a liquid collecting means comprising an absorbent inert member, containing a reagent substance which reacts with selected drug, in a position in close proximity to an eye of the patient for collecting tear fluid therefrom and allowing the tear fluid collected to come into contact with said reagent substance during a period sufficient to permit the development of the reaction which has to be physically detectable. It is mentioned that this method provides a readily indication of she level of said drug in the body because the tear fluid is less complex then other body fluids such as blood. Nevertheless, this assay permits only qualitative or semi-quantitative drug detection.
Although simplicity is an important quality when dealing with monitoring methods, the accuracy of the assay is crucial in the control of diseases, e.g. tuberculosis, specially to measure small quantities of drugs in complex body fluids, such as blood. In the U.S. Pat. No. 4,656,141 it is proposed a high-performance liquid chromatography process for detecting the presence of trace amounts of non-fluorescent soluble compounds each having at least one labile hydrogen atom in a carrier solution by adding a non-fluorescent quinone which is reducible to a fluorescent hydroquinone, and irradiating the resulting solution in the absence of oxygen with light of sufficient energy to cause the quinone to be reduced to a hydroquinone.
Preferably both quantitative and analytical methods should be used to follow the patient on a repetitive basis to ensure that the patient is indeed ingesting the prescribed amounts of medication in the proper manner and responding as expected. Moreover, in control programmes of Public Health Services, confident monitoring of treatment is crucial. Tuberculosis Control Program may be cited as a representative example of this approach and Rifampicin as a highly potent drug widely used for tuberculosis treatment.
An efficient follow up the other drugs treatment performance is also important. Examples are anti-retroviral drugs, such as proteinase or reverse transcriptase inhibitors, e.g. 2′,3′-dideoxyinosine (ddI), 2′,3′-dideoxycytidine (ddC) or 3′-azido-2,3′-dideoxythymidine (AZT) (see Frijus-Plessen N., Michaelis H. C., Forth H. e Kahl G. F. (1990). “Determination of 3′-azido-3′-deoxythymidine, 2′,3′-dideoxycytidine, 3′-fluoro-3′-deoxythymidine and 2′,3′-dideoxyinosine in biological samples by high-performance liquid chromatography”. Chrombio. Elsevier Science Publishers B. V. Amsterdam. 534: 101-107), anti-fungal drugs, e.g. itraconazole which is also used in anti-leishmanial chemotherapy. (Anon: British Society for Antimicrobial Chemotherapy Working Party: Laboratory monitoring of antifungal chemotherapy.
The Lancet
. Vol. 337. pp. 1577-1580. 1991) or antimonials, the most used anti-leishmanial drug (World Health Organization.
Tropical Disease Research. Twelfth Programme Report
. World Health Organization Geneva, Switzerland. Pp 139.1995).
In the case of patients with tuberculosis, there has been increasing interest in the determination of serum levels of the main antituberculosis drugs, in particular the most used rifampicin medication. The usual methods for rifampicin assay are colorimetry, microbiology and high-performance liquid chromatography. In the beginning, microbiological assays were employed by using
Sarcina lutea
or
Staphylococcus aureus
. Examples are described in: Furesz S., Scotti, P., Pallanza R., Mapelli E. (1967). “Rifampicin: A new, rifampicin. III Absorption, distribution and elimination in man”. Arzneim-Forsch. 17: 534-7; Boman, G. (1974). “Serum concentration and half-life of rifampicin after simultaneous oral administration of aminosalicylic acid or isoniazid”. Europ J Clin Pharmacol. 7: 217-25; Dickinson, J. M., Aber, V. R., Allen, B. W., Ellard, A., Mitchison, D. A. (1974). “Assay of rifampicin in serum”. J Clin Path. 27: 457-62; Buniva, G., Pagani, V., Carozzi, A. (1983). “Bioavailability of rifampicin capsules”. Int J Clin Pharmacol Therapy Toxicol. 21: 404-9; Immanuel, C., Jayasankar, K., Narayana, A. S. L., Saema, G. R. (1985). “Self-induction of rifampicin metabolism in man”. Indian Med Res. 82: 381-7. However, the precision of such methods is generally poorer than would be expected with HPLC methods.
Colorimetric methods are interesting under the point of view of easier accomplishing. The procedures or such methods are described in: Maggi, N., Fures
Barroso Eduardo W.
Ferreira Milton F.
Gemal André L.
Luiza Vera L.
Fundacao Oswaldo Cruz (Fiocruz)
Ludlow Jan M.
Nixon & Vanderhye P.C.
LandOfFree
Monitoring patient compliance and bioavailability of drugs... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monitoring patient compliance and bioavailability of drugs..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monitoring patient compliance and bioavailability of drugs... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3255965